Medical Conference Calendar 2026

Lipid disorders, atherosclerosis, PCSK9 inhibitors, ANGPTL3, Lp(a) therapies. PCSK9 outcomes trials, PCSK9 siRNA data. Novartis, Regeneron/Sanofi, Amgen lipid pipeline.

MASH/NAFLD, viral hepatitis B/D/C, liver fibrosis, cirrhosis, HCC. European counterpart to AASLD. Gilead, GSK, AstraZeneca, Novartis, Roche liver programs. bulevirtide, pemvidutide, resmetirom long-term data.

Largest oncology conference. Major readouts for solid tumors, immunotherapy, hematologic cancers.

European nephrology. CKD, IgA nephropathy, glomerulonephritis, dialysis. Finerenone, SGLT2+MRA combinations, semaglutide in CKD. AstraZeneca, Bayer, Novo Nordisk. Complements ASN Kidney Week.

Sleep disorders — insomnia, OSA, narcolepsy, idiopathic hypersomnia. GLP-1 and OSA crossover trials, new orexin antagonists, pitolisant. Growing importance as obesity/OSA overlap increases.

European rheumatology and musculoskeletal disease. Often TNF, IL-6, JAK data.

Premier European hematology congress. 4,000+ abstracts, complements ASH. AML, CLL, lymphoma, myeloma, hemoglobinopathies, bispecific antibodies. J&J, AbbVie, BMS, Roche, Pfizer, Sanofi.

Hormonal disorders, thyroid, adrenal, obesity, growth disorders.

Key for GLP-1 agonists, insulin, SGLT2 inhibitors, obesity drugs.

Thrombosis, hemostasis, bleeding disorders. Hemophilia (gene therapy, fitusiran, emicizumab), VTE, anticoagulation. Sanofi, Pfizer, Roche, BioMarin, Alnylam, Novo Nordisk.

European cardiovascular data. Often presents pivotal cardiovascular outcomes trials.

European respiratory. IPF, asthma, COPD, lung cancer readouts.

World's largest lung cancer conference. NSCLC, SCLC, mesothelioma. EGFR, ALK, MET, KRAS, IO combinations. AstraZeneca, Roche, Merck, BMS, Pfizer, Novartis present landmark data here.

European dermatology. 5,300+ abstracts in 2025. Atopic dermatitis, psoriasis, HS late-breaking trials. Tralokinumab, icotrokinra, rocatinlimab, izokibep data typically presented here.

Premier European oncology meeting. Often European data complements ASCO US data.

European diabetes and metabolic disease data. Often first presentation of EU trial data.

Multiple sclerosis focused. Key venue for new MS DMT data.

Europe's largest applied neuroscience and psychiatry meeting. Depression, schizophrenia, bipolar, anxiety, ADHD. J&J, Pfizer, AstraZeneca, Lundbeck CNS pipelines.

Broad infectious disease — antibiotics, antivirals, vaccines, fungal infections.

Largest US ophthalmology conference (~20,000 attendees). Wet AMD, diabetic retinopathy, geographic atrophy, gene therapy. Roche (faricimab/Vabysmo), Regeneron (Eylea HD), Novartis.

Pulmonology and critical care — asthma, COPD, PAH, IPF, sleep medicine. Sotatercept (Merck) PAH data, dupilumab long-term, GLP-1 and OSA. Complements ATS with fall conference.

CKD, dialysis, transplant, IgA nephropathy. Key for new SGLT2 and finerenone data.

Interventional cardiology — structural heart, ACS, coronary intervention. Anticoagulant and antiplatelet drug trials alongside devices. Roche, BMS, AstraZeneca, Bayer.

Premier obesity clinical science conference. GLP-1 revolution: semaglutide, tirzepatide secondary analyses, real-world data, new obesity drugs. Novo Nordisk, Eli Lilly, AstraZeneca, Pfizer, Roche obesity programs.

Key for checkpoint inhibitors, CAR-T, cancer vaccines, and immuno-oncology combinations.

Stroke, heart failure, hypertension, atrial fibrillation readouts.

RA, PsA, SLE, ankylosing spondylitis, IBD. Key for JAK inhibitors, IL-17/23 data.

NASH/MASH, HCC, hepatitis B/C, liver transplant. Key for FXR agonists, resmetirom, thyroid hormone analogs.

Neuro-oncology — glioblastoma, brain metastases, CNS lymphoma. CAR-T in GBM, checkpoint inhibitors in CNS tumors. Roche, Merck, BMS, AstraZeneca, emerging CAR-T programs.

The primary conference for Alzheimer's clinical trial readouts. Distinct from AD/PD (which is broader). Biogen/Eisai (lecanemab), Eli Lilly (donanemab), Roche (gantenerumab), Merck, Novo Nordisk CNS programs present here.

Key venue for leukemia, lymphoma, myeloma, and blood disorder data.